Literature DB >> 25267569

The prognostic significance of Smad3, Smad4, Smad3 phosphoisoform expression in esophageal squamous cell carcinoma.

Soo Youn Cho1, Sang Yun Ha, Song-Mei Huang, Jeong Hoon Kim, Myung Soo Kang, Hae-Yong Yoo, Hyeon-ho Kim, Cheol-Keun Park, Sung-Hee Um, Kyung-Hee Kim, Seok-Hyung Kim.   

Abstract

Smad3 functions as an integrator of diverse signaling, including transforming growth factor β signaling and the function of Smad3 is complexly regulated by differential phosphorylation at various sites of Smad3. Despite the importance of Smad3 and its various phosphoisoforms, their prognostic significance has rarely been studied. In this study, we demonstrated the prognostic significance of Smad3, its phosphoisoforms, and Smad4 expression by immunohistochemistry in 126 esophageal squamous cell carcinomas. The phosphoisoforms of Smad3 studied in this article included phosphorylation at C-terminal (pSmad3C)(Ser(423/425)) and phosphorylation at the linker region (pSmad3L)(Ser(213)). High expression of Smad3 was associated with shorter overall survival. Co-existence of high expression of pSmad3L(S213) and low expression of pSmad3C(S423/425) were associated with advanced N stage and an independent prognostic factor for overall [hazard ratio (HR) 2.03, 95 % confidence interval (CI) (1.10-3.75), p = 0.023] and disease-free survival [HR 2.41, 95 % CI (1.32-4.39), p = 0.004]. In conclusion, co-existence of high pSmad3L(Ser(213)) expression and low pSmad3C(Ser(423/425)) expression can be considered as immunohistochemical biomarkers for predicting prognosis as well as future therapeutic targets. In addition, our results of combinatory effect of differential phosphorylation of Smad3 on prognosis suggest the mode of action of Smad3 might be logically determined by its phosphorylation pattern.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25267569     DOI: 10.1007/s12032-014-0236-9

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  32 in total

1.  Expression of EMMPRIN and matriptase in esophageal squamous cell carcinoma: correlation with clinicopathological parameters.

Authors:  M-F Cheng; C Tzao; W-C Tsai; W-H Lee; A Chen; H Chiang; L-F Sheu; J-S Jin
Journal:  Dis Esophagus       Date:  2006       Impact factor: 3.429

Review 2.  Specificity and versatility in tgf-beta signaling through Smads.

Authors:  Xin-Hua Feng; Rik Derynck
Journal:  Annu Rev Cell Dev Biol       Date:  2005       Impact factor: 13.827

3.  Acceleration of Smad2 and Smad3 phosphorylation via c-Jun NH(2)-terminal kinase during human colorectal carcinogenesis.

Authors:  Hideo Yamagata; Koichi Matsuzaki; Shigeo Mori; Katsunori Yoshida; Yoshiya Tahashi; Fukiko Furukawa; Go Sekimoto; Toshihiko Watanabe; Yoshiko Uemura; Noriko Sakaida; Kazuhiko Yoshioka; Yasuo Kamiyama; Toshihito Seki; Kazuichi Okazaki
Journal:  Cancer Res       Date:  2005-01-01       Impact factor: 12.701

Review 4.  TGFbeta in Cancer.

Authors:  Joan Massagué
Journal:  Cell       Date:  2008-07-25       Impact factor: 41.582

5.  TGF-beta and HGF transmit the signals through JNK-dependent Smad2/3 phosphorylation at the linker regions.

Authors:  Shigeo Mori; Koichi Matsuzaki; Katsunori Yoshida; Fukiko Furukawa; Yoshiya Tahashi; Hideo Yamagata; Go Sekimoto; Toshihito Seki; Hirofumi Matsui; Mikio Nishizawa; Jun-ichi Fujisawa; Kazuichi Okazaki
Journal:  Oncogene       Date:  2004-09-23       Impact factor: 9.867

6.  Transforming growth factor-{beta}-inducible phosphorylation of Smad3.

Authors:  Guannan Wang; Isao Matsuura; Dongming He; Fang Liu
Journal:  J Biol Chem       Date:  2009-02-13       Impact factor: 5.157

7.  Hepatitis B virus X protein shifts human hepatic transforming growth factor (TGF)-beta signaling from tumor suppression to oncogenesis in early chronic hepatitis B.

Authors:  Miki Murata; Koichi Matsuzaki; Katsunori Yoshida; Go Sekimoto; Yoshiya Tahashi; Shigeo Mori; Yoshiko Uemura; Noriko Sakaida; Junichi Fujisawa; Toshihito Seki; Kazuki Kobayashi; Koutaro Yokote; Kazuhiko Koike; Kazuichi Okazaki
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

8.  Inhibition of c-Jun NH2-terminal kinase switches Smad3 signaling from oncogenesis to tumor- suppression in rat hepatocellular carcinoma.

Authors:  Hiromitsu Nagata; Etsuro Hatano; Masaharu Tada; Miki Murata; Koji Kitamura; Hiroyuki Asechi; Masato Narita; Atsuko Yanagida; Nobuyuki Tamaki; Shintaro Yagi; Iwao Ikai; Koichi Matsuzaki; Shinji Uemoto
Journal:  Hepatology       Date:  2009-06       Impact factor: 17.425

9.  Reversible Smad-dependent signaling between tumor suppression and oncogenesis.

Authors:  Go Sekimoto; Koichi Matsuzaki; Katsunori Yoshida; Shigeo Mori; Miki Murata; Toshihito Seki; Hirofumi Matsui; Jun-ichi Fujisawa; Kazuichi Okazaki
Journal:  Cancer Res       Date:  2007-06-01       Impact factor: 12.701

10.  Roles of TGFβ signaling Smads in squamous cell carcinoma.

Authors:  Gangwen Han; Xiao-Jing Wang
Journal:  Cell Biosci       Date:  2011-12-28       Impact factor: 7.133

View more
  2 in total

1.  The Relationship Between Single Nucleotide Polymorphisms of SMAD3/SMAD6 and Risk of Esophageal Squamous Cell Carcinoma in Chinese Population.

Authors:  Jinjie Yu; Yunpeng Dong; Weifeng Tang; Huiwen Pan; Lu Lv; Tao Long; Qiang Zhou; Junqing Qi; Jianchao Liu; Guowen Ding; Jun Yin; Lijie Tan
Journal:  Pharmgenomics Pers Med       Date:  2020-08-24

2.  Hypoxia Selectively Increases a SMAD3 Signaling Axis to Promote Cancer Cell Invasion.

Authors:  Karine Brochu-Gaudreau; Martine Charbonneau; Kelly Harper; Claire M Dubois
Journal:  Cancers (Basel)       Date:  2022-06-01       Impact factor: 6.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.